fda warning on semaglutide Gives Ozempic New Side Effect FDA Approves Semaglutide for New

However, both medications can independently affect the gastrointestinal system , which warrants consideration

GLP-1 receptor agonists represent a paradigm shift in obesity management, producing clinically meaningful weight reduction beyond what has been achievable with previous drug classes (Wilding, New England Journal of Medicine )

How Zepbound and Ozempic Work How Zepbound Works Zepbound activates two hormone pathways: GIP and GLP-1

As a motilin receptor agonist, erythromycin exerts prokinetic effects on the upper GI tract, and emerging studies suggest it may reverse GLP-1-related delays in gastric emptying [13,14]

While gastrointestinal side effects are common with semaglutide, certain symptoms warrant prompt medical evaluation